A5016497323- Palliative Care and End-of-Life Issues
- Intensive Care Unit Cognitive Disorders
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Hepatocellular Carcinoma Treatment and Prognosis
- Respiratory Support and Mechanisms
- Healthcare Decision-Making and Restraints
- Patient-Provider Communication in Healthcare
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Autoimmune Bullous Skin Diseases
- Anesthesia and Sedative Agents
- Pharmacological Receptor Mechanisms and Effects
- Chronic Lymphocytic Leukemia Research
- Family and Patient Care in Intensive Care Units
- Immunodeficiency and Autoimmune Disorders
- Patient Dignity and Privacy
- Tuberculosis Research and Epidemiology
- Grief, Bereavement, and Mental Health
- Lymphatic Disorders and Treatments
- Eosinophilic Esophagitis
- Neutropenia and Cancer Infections
- Pneumonia and Respiratory Infections
- Frailty in Older Adults
- Pneumocystis jirovecii pneumonia detection and treatment
- Ovarian cancer diagnosis and treatment
Seirei Mikatabara General Hospital
2021-2024
Seirei Hamamatsu General Hospital
2023-2024
RELX Group (United States)
2023-2024
Seirei Social Welfare Community
2021
Iwata City Hospital
2019
National Hospital Organization
2010
There are very few data on serum procalcitonin (PCT) levels in pulmonary tuberculosis (PTB) patients who negative for HIV. We assessed PCT consecutive diagnosed with or community-acquired pneumonia (CAP) admission to discriminate between PTB and CAP, examined the value of prognostic factors PTB. 102 patients, 62 CAP 34 healthy volunteers were enrolled. Serum was significantly lower than (mean ± sd 0.21 0.49 versus 4.10 8.68 ng·mL⁻¹; p < 0.0001). By receiver-operating characteristic curve...
An 84-year-old man visited our hospital with a prolonged productive cough. Chest computed tomography showed thick wall cavity and bilateral consolidations. Laboratory findings revealed peripheral blood eosinophilia, increased total IgE elevated myeloperoxidase anti-neutrophil cytoplasmic antibody. Specific IgG antibodies an immediate skin reaction against Aspergillus positive results. The histological of the lung parenchyma were compatible eosinophilic pneumonia bronchial biopsy vasculitis....
Abstract Background How clinicians treat patients with terminal dyspnea widely varies, which could hamper quality care. We visualized comprehensive pharmacological treatment delivered by palliative care physicians. Aim To examine adherence to a algorithm for dyspnea, and explore its outcomes during 48 h. Design A multicenter cohort study at five sites (February 2020 June 2021). Setting/Participants prospectively enrolled consecutive advanced cancer, Eastern Cooperative Oncology Group...
Abstract Background Malignant ascites often causes discomfort in advanced cancer patients. Paracentesis is the most common treatment modality, but it requires frequently repeated treatment. Cell-free and concentrated reinfusion therapy (CART) may prolong paracentesis interval, controlled trials are lacking. We assessed feasibility of a randomized trial CART vs. alone for patients with refractory malignant ascites. Methods This study was an open-label, fast-track, controlled, trial. Patients...
At present, the world is undergoing successive waves of COVID-19 pandemic. When becomes severe, it causes respiratory failure and symptoms dyspnoea. The patient's dyspnoea worsens to IPOS 3. One patient admitted our medical institution developed severe illness characterised by hypoxaemia In addition disease-modifying treatments such as remdesivir dexamethasone, we administered morphine relieve his Surprisingly, observed an improvement in both
Abstract Purpose: Malignant ascites often causes discomfort in advanced cancer patients. Cell-free and concentrated reinfusion therapy (CART) is one treatment modality, but controlled trials are lacking. We assessed the feasibility of a randomized trial CART vs. paracentesis alone for patients with refractory malignant ascites. Methods: This study was an open-label, fast-track, controlled, trial. Patients admitted to four designated hospitals who received no further anticancer treatments...
【目的】緩和ケア医が苦痛の評価を行う上で知っておくことが必要と考える方言を収集する.【方法】2020年2月から4月に緩和医療専門医・認定医762名を対象とした全国質問紙調査を実施した.緩和ケア医が苦痛の評価を行う上で知っておくことが必要と考える方言とその意味を自由記述で質問し,症状別に分類した.【結果】有効回答492名(64.8%).233名(47.4%)が方言として116語を挙げ,苦痛を表現する方言は101語であった.「倦怠感・特定できない苦痛・全体的な調子の悪さ」(N=62),「疼痛」(N=13),「呼吸器・循環器症状」,「精神症状」(各N=8),「消化器症状」,「神経・筋・皮膚症状」(各N=5)であった.【結語】緩和ケア医が苦痛の評価を行う上で知っておくことが必要と考える方言とその意味が明らかになった.苦痛の適切な評価のために,苦痛を表す様々な方言があることを理解することが必要である.